Grant✓ Small businesses may apply
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
National Institutes of Health
- Opportunity #
- PAR-24-304
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.394
- Status
- posted
- Posted
- Oct 10, 2024
- Closes
- Oct 14, 2026
- Funding instrument
- Grant
- Category
- Education, Health
- Cost sharing required
- No
Who can apply
- •Public and State controlled institutions of higher education
- •For profit organizations other than small businesses
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •State governments
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •Independent school districts
- •Public housing authorities/Indian housing authorities
- •Native American tribal governments (Federally recognized)
- •County governments
- •Private institutions of higher education
- •Special district governments
- •City or township governments
- •Small businesses
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
Through this Notice of Funding Opportunity (NOFO) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this NOFO is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this NOFO encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.
Contact
National Institutes of Health · grantsinfo@nih.gov